Cellular Medicines
-
Mesoblast Board of Directors Appoints New Leadership
Mesoblast is transitioning to commercialization with board leadership changes. Jane Bell steps down as Chair but remains a director, while Philip Facchina assumes the Chair role. Lyn Cobley will lead the Audit and Risk Committee. These changes aim to strengthen U.S. commercial capabilities and drive shareholder value as Mesoblast focuses on market engagement for its cellular medicines, including Ryoncil®.
